COPD and biologic treatment: state of the art

Abstract

Purpose of review Chronic Obstructive Pulmonary Disease (COPD) is a common, heterogeneous disease associated with abnormal inflammatory response of the lung to noxious particles and gases. The progression of disease leads to respiratory failure, disability and premature death. Although recent progress in reducing the global burden of many chronic disease, such as heart disease and cancer, mortality and morbidity due to COPD continue to increase despite of cigarette smoking worldwide policy. Additionally, diagnostic and therapeutic options have not changed in decades. While patients affected by other respiratory disease may benefit with a personalized precision medicine, thanks to the new biological treatment, to date, there is no biological treatment available for COPD. COPD is generally a neutrophils-predominant disease but approximately 40% of patients with COPD had also an eosinophilic airway inflammation. Recent findings different Phase III trials have been recently performed to evaluate the efficacy and safety of several biological treatments, mostly against eosinophilic inflammation and, to date, some of this trial, still ongoing have promising results. Summary This review resumes the rationale, the attempts of biological treatment in COPD and latest promising results.

Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects

“…Some studies have suggested that smoking is the main environmental factor triggering COPD, but other factors also include airway hyperresponsiveness, sex, genetics, occupation, lung growth, and development[ 101 , 102 ]. Currently available treatment methods for COPD, which mainly focus on treating the symptoms and slowing the progression of these disorders, include anti-inflammatory drugs, corticosteroids, long-acting muscarinic antagonists, and β2-adrenergic receptor agonists[ 103 , 104 ]. These treatments may help minimize airflow limitation and future exacerbations but cannot reverse lung damage or improve quality of life in patients with COPD.…”

Promising Intestinal Microbiota Associated with Clinical Characteristics of COPD Through Integrated Bioinformatics Analysis

“…Chronic obstructive pulmonary disease (COPD) is an incurable chronic respiratory disease, characterized by persistent respiratory symptoms and airflow restriction due to airway or alveolar abnormalities. 1 The morbidity and mortality of COPD are rising every year worldwide and the World Health Organization estimates that COPD will be the third leading cause of death in the world by 2030. 2 Although our understanding of COPD is improving, the pathological mechanism of COPD has not been fully elucidated.…”